Amylyx Pharmaceuticals (AMLX) Operating Leases (2022 - 2026)

Amylyx Pharmaceuticals' Operating Leases history runs 5 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Operating Leases rose 1268.81% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (up 1268.81% YoY), while the FY2025 annual figure was $4.7 million, up 914.69% from the prior year.
• Operating Leases was $4.5 million for Q1 2026 at Amylyx Pharmaceuticals, down from $4.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.8 million in Q1 2022 to a low of $327000.0 in Q1 2025.
• Historically, Operating Leases has averaged $3.5 million across 5 years, with a median of $4.2 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Operating Leases slumped 76.62% in 2024, then soared 1268.81% in 2026.
• A 5-year view of Operating Leases shows it stood at $4.2 million in 2022, then tumbled by 53.27% to $2.0 million in 2023, then tumbled by 76.62% to $463000.0 in 2024, then surged by 914.69% to $4.7 million in 2025, then decreased by 4.73% to $4.5 million in 2026.
• The last three Operating Leases figures came in at $4.5 million (Q1 2026), $4.7 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.